LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 129

Search options

  1. Book ; Thesis: Neue Aromatasehemmer als systemische Therapie des fortgeschrittenen postmenopausalen Mammakarzinoms

    Hilpert, Felix

    klinische Wirksamkeit, Verträglichkeit sowie prognostische Bedeutung klinischer, konstitutioneller und laborchemischer Faktoren

    1996  

    Author's details vorgelegt von Felix Hilpert
    Language German
    Size 81 Bl. : graph. Darst.
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Hamburg, Univ., Diss., 1997
    HBZ-ID HT011141195
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  2. Book ; Conference proceedings: Ovarialkarzinom

    Du Bois, Andreas / Pfisterer, Jacobus / Sehouli, Jalid / Hilpert, Felix / Harter, Philipp

    aktueller Stand der Therapie des Ovarialkarzinomrezidivs nach der 5. Ovarian Cancer Consensus Conference 11/2015

    (Thieme-Praxis-Report ; 8. Jahrgang, Heft 5 (Mai 2016))

    2016  

    Author's details Autoren Prof. Dr. Andreas du Bois, Prof. Dr. Jacobus Pfisterer, Prof. Dr. Jalid Sehouli, Prof. Dr. Felix Hilpert, Dr. med. Philipp Harter
    Series title Thieme-Praxis-Report ; 8. Jahrgang, Heft 5 (Mai 2016)
    Collection
    Language German
    Size 11 Seiten, Illustrationen
    Publisher Thieme
    Publishing place Stuttgart
    Publishing country Germany
    Document type Book ; Conference proceedings
    HBZ-ID HT019005960
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article: Ovarialkarzinomrezidiv: Ausblick zum Therapiealgorithmus

    Hilpert, Felix

    TZM-News : Sonderausgabe

    2018  Volume -, Issue 1, Page(s) 10

    Language German
    Document type Article
    ZDB-ID 2711416-8
    Database Current Contents Medicine

    More links

    Kategorien

  4. Article ; Online: Patient-reported outcomes in ovarian cancer: are they key factors for decision making?

    Hilpert, Felix / Du Bois, Andreas

    Expert review of anticancer therapy

    2018  Volume 18, Issue sup1, Page(s) 3–7

    Abstract: Introduction: Patient-reported outcomes (PROs), including quality-of-life considerations, are increasingly becoming key factors in clinical decision making. Areas covered: This review provides an overview of the current status of PROs in guiding ... ...

    Abstract Introduction: Patient-reported outcomes (PROs), including quality-of-life considerations, are increasingly becoming key factors in clinical decision making. Areas covered: This review provides an overview of the current status of PROs in guiding clinical trial design and clinical decision making in patients with ovarian cancer and previews the future potential of PROs in these settings. Expert commentary: In ovarian cancer, considerable discord exists between patients and physicians regarding perceived symptom burden. During maintenance therapy, it is important that the most appropriate PROs (i.e. endpoints and respective measuring tools) are selected to evaluate patients. Research continues into identifying PROs most likely to facilitate and enhance reporting of symptoms, adverse events, and subjective benefit. Some recent studies performed in ovarian cancer, such as the SOLO2/ENGOT-Ov21 and AURELIA trials, have reported valuable PRO data pertaining to the Trial Outcome Index (TOI) score, quality-adjusted progression-free survival (QAPFS), and time without symptoms and toxicity (TWiST). In future, PROs are likely to become increasingly important in clinical trial design, regulatory procedures, and provision of valuable prognostic information to patients and physicians in clinical practice.
    MeSH term(s) Clinical Decision-Making ; Clinical Trials as Topic/methods ; Female ; Humans ; Ovarian Neoplasms/drug therapy ; Ovarian Neoplasms/pathology ; Patient Reported Outcome Measures ; Prognosis ; Quality of Life ; Research Design
    Language English
    Publishing date 2018-09-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2018.1516146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Nekrolog – Nachruf auf Dr. med. Horst Ostertag

    Lindner, Christoph / Hilpert, Felix

    Geburtshilfe und Frauenheilkunde

    2018  Volume 78, Issue 08, Page(s) 761–761

    Language German
    Publishing date 2018-08-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 80111-2
    ISSN 1438-8804 ; 0016-5751 ; 1615-3359
    ISSN (online) 1438-8804
    ISSN 0016-5751 ; 1615-3359
    DOI 10.1055/a-0635-7829
    Database Thieme publisher's database

    More links

    Kategorien

  6. Article ; Online: Comparative analysis of surface coating properties of five hydrophobins from Aspergillus nidulans and Trichoderma reseei.

    Winandy, Lex / Hilpert, Felix / Schlebusch, Oleksandra / Fischer, Reinhard

    Scientific reports

    2018  Volume 8, Issue 1, Page(s) 12033

    Abstract: Fungal hydrophobins are small amphiphilic proteins that self-assemble into monolayers on hydrophobic:hydrophilic interfaces and can be used for surface coatings. Because e.g. Aspergillus nidulans contains six different hydrophobins, it is likely that ... ...

    Abstract Fungal hydrophobins are small amphiphilic proteins that self-assemble into monolayers on hydrophobic:hydrophilic interfaces and can be used for surface coatings. Because e.g. Aspergillus nidulans contains six different hydrophobins, it is likely that they have different properties and are used for different "applications" in the fungus. We established a method for recombinant production of different class hydrophobins in Escherichia coli. We produced DewA, DewC, DewD, DewE from A. nidulans and HFBI from Trichoderma reesei and compared surface coating properties of these hydrophobins. All tested proteins formed coatings on glass, strongly increasing the hydrophobicity of the surface, and showed emulsion-stabilizing properties. But whereas the typical class I hydrophobin DewA formed the most stable coating on glass, the intermediate class hydrophobins DewE and DewD were more effective in stabilization of oil:water emulsions. This work gives insights into correlations between structural characteristics of hydrophobins and their behaviour as surface binding agents. It could help with the clarification of their biological functions and lead to novel biotechnological applications.
    MeSH term(s) Amino Acid Sequence ; Aspergillus nidulans/metabolism ; Fungal Proteins/chemistry ; Fungal Proteins/metabolism ; Hydrophobic and Hydrophilic Interactions ; Microscopy, Atomic Force ; Surface Properties ; Trichoderma/metabolism ; Water/chemistry
    Chemical Substances DEWA protein, Asperigillus nidulans ; Fungal Proteins ; Water (059QF0KO0R)
    Language English
    Publishing date 2018-08-13
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-018-29749-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.

    Gass, Paul / Thiel, Falk C / Häberle, Lothar / Ackermann, Sven / Theuser, Anna-Katharin / Hummel, Nadine / Boehm, Sibylle / Kimmig, Rainer / Reinthaller, Alexander / Becker, Sven / Hilpert, Felix / Janni, Wolfgang / Vergote, Ignace / Harter, Phlipp / Emons, Julius / Hein, Alexander / Beckmann, Matthias W / Fasching, Peter A / Pöschke, Patrik

    Gynecologic oncology

    2024  Volume 183, Page(s) 25–32

    Abstract: Background: Before the era of immunotherapies and antibody-drug conjugates, there were limited chemotherapeutic options for patients with recurrent and metastatic cervical cancer. Combination therapies with cisplatin have shown some superiority over ... ...

    Abstract Background: Before the era of immunotherapies and antibody-drug conjugates, there were limited chemotherapeutic options for patients with recurrent and metastatic cervical cancer. Combination therapies with cisplatin have shown some superiority over monotherapy. This study examined platinum-free treatment regimens, comparing a combination of topotecan and paclitaxel (TP) with topotecan and cisplatin (TC) in patients with recurrent or metastatic cervical cancer, with or without prior platinum-based treatment.
    Methods: The AGO-Zervix-1 Study (NCT01405235) is a prospective, randomized phase III study in which patients were randomly assigned at a 1:1 ratio to treatment within the control arm with topotecan (0.75 mg/m
    Results: Median overall survival in the TP arm was 9.6 months, compared with 12.0 months in the TC arm (log-rank test, P = 0.33). Median progression-free survival rates were 4.4 months with TP and 4.2 months with TC (log-rank test, P = 0.47). Leukopenia and nausea/vomiting were more frequent in the cisplatin-containing arm. Otherwise, toxicity profiles were comparable. There were no differences in FACT-G-assessed quality of life.
    Conclusion: Platinum-based combination chemotherapy remains the standard of care chemotherapy regimen for patients with recurrent or metastatic cervical cancer.
    Language English
    Publishing date 2024-03-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 801461-9
    ISSN 1095-6859 ; 0090-8258
    ISSN (online) 1095-6859
    ISSN 0090-8258
    DOI 10.1016/j.ygyno.2024.03.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Mechanistic Insight into Solution-Based Atomic Layer Deposition of CuSCN Provided by In Situ and Ex Situ Methods

    Hilpert, Felix / Liao, Pei-Chun / Franz, Evanie / Koch, Vanessa M. / Fromm, Lukas / Topraksal, Ece / Görling, Andreas / Smith, Ana-Sunc̆ana / Barr, Maïssa K. S. / Bachmann, Julien / Brummel, Olaf / Libuda, Jörg

    ACS Applied Materials & Interfaces. 2023 Apr. 05, v. 15, no. 15 p.19536-19544

    2023  

    Abstract: Solution-based atomic layer deposition (sALD) processes enable the preparation of thin films on nanostructured surfaces while controlling the film thickness down to a monolayer and preserving the homogeneity of the film. In sALD, a similar operation ... ...

    Abstract Solution-based atomic layer deposition (sALD) processes enable the preparation of thin films on nanostructured surfaces while controlling the film thickness down to a monolayer and preserving the homogeneity of the film. In sALD, a similar operation principle as in gas-phase ALD is used, however, with a broader range of accessible materials and without requiring expensive vacuum equipment. In this work, a sALD process was developed to prepare CuSCN on a Si substrate using the precursors CuOAc and LiSCN. The film growth was studied by ex situ atomic force microscopy (AFM), analyzed by a neural network (NN) approach, ellipsometry, and a newly developed in situ infrared (IR) spectroscopy experiment in combination with density functional theory (DFT). In the self-limiting sALD process, CuSCN grows on top of an initially formed two-dimensional (2D) layer as three-dimensional spherical nanoparticles with an average size of ∼25 nm and a narrow particle size distribution. With increasing cycle number, the particle density increases and larger particles form via Ostwald ripening and coalescence. The film grows preferentially in the β-CuSCN phase. Additionally, a small fraction of the α-CuSCN phase and defect sites form.
    Keywords atomic force microscopy ; density functional theory ; equipment ; nanoparticles ; particle size distribution ; spectroscopy ; solution atomic layer deposition ; liquid phase ; in situ IR spectroscopy ; copper thiocyanate ; neural network ; liquid atomic layer deposition
    Language English
    Dates of publication 2023-0405
    Size p. 19536-19544.
    Publishing place American Chemical Society
    Document type Article ; Online
    ISSN 1944-8252
    DOI 10.1021/acsami.2c16943
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  9. Article ; Online: Mechanistic Insight into Solution-Based Atomic Layer Deposition of CuSCN Provided by In Situ and Ex Situ Methods.

    Hilpert, Felix / Liao, Pei-Chun / Franz, Evanie / Koch, Vanessa M / Fromm, Lukas / Topraksal, Ece / Görling, Andreas / Smith, Ana-Sunc Ana / Barr, Maïssa K S / Bachmann, Julien / Brummel, Olaf / Libuda, Jörg

    ACS applied materials & interfaces

    2023  Volume 15, Issue 15, Page(s) 19536–19544

    Abstract: Solution-based atomic layer deposition (sALD) processes enable the preparation of thin films on nanostructured surfaces while controlling the film thickness down to a monolayer and preserving the homogeneity of the film. In sALD, a similar operation ... ...

    Abstract Solution-based atomic layer deposition (sALD) processes enable the preparation of thin films on nanostructured surfaces while controlling the film thickness down to a monolayer and preserving the homogeneity of the film. In sALD, a similar operation principle as in gas-phase ALD is used, however, with a broader range of accessible materials and without requiring expensive vacuum equipment. In this work, a sALD process was developed to prepare CuSCN on a Si substrate using the precursors CuOAc and LiSCN. The film growth was studied by ex situ atomic force microscopy (AFM), analyzed by a neural network (NN) approach, ellipsometry, and a newly developed in situ infrared (IR) spectroscopy experiment in combination with density functional theory (DFT). In the self-limiting sALD process, CuSCN grows on top of an initially formed two-dimensional (2D) layer as three-dimensional spherical nanoparticles with an average size of ∼25 nm and a narrow particle size distribution. With increasing cycle number, the particle density increases and larger particles form via Ostwald ripening and coalescence. The film grows preferentially in the β-CuSCN phase. Additionally, a small fraction of the α-CuSCN phase and defect sites form.
    Language English
    Publishing date 2023-04-05
    Publishing country United States
    Document type Journal Article
    ISSN 1944-8252
    ISSN (online) 1944-8252
    DOI 10.1021/acsami.2c16943
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.

    Wimberger, Pauline / Pfisterer, Jacobus / du Bois, Andreas / Hilpert, Felix / Kerkmann, Markus / Sehouli, Jalid / Mahner, Sven / de Gregorio, Nikolaus / Hanker, Lars / Heitz, Florian / Marmé, Frederik / Woelber, Linn / Holtmann, Laura / Elser, Gabriele / Harter, Philipp

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

    2023  Volume 33, Issue 7, Page(s) 1083–1089

    Abstract: Objective: The quality assurance program for ovarian cancer (QS-OVAR) evaluates the implementation of treatment standards and impact on survival for International Federation of Gynecology and Obstetrics (FIGO) stage I ovarian cancer.: Methods: ... ...

    Abstract Objective: The quality assurance program for ovarian cancer (QS-OVAR) evaluates the implementation of treatment standards and impact on survival for International Federation of Gynecology and Obstetrics (FIGO) stage I ovarian cancer.
    Methods: Patients with a first diagnosis of ovarian cancer, diagnosed in the third quarter of 2004, 2008, 2012, and 2016, were documented. Surgical quality was categorized as optimal (maximum one surgical item missing) versus suboptimal (≥2 surgical items missing). Chemotherapy was defined as optimal according to national guidelines. Treatment quality was classified into four categories: surgery and chemotherapy were optimal, optimal surgery and suboptimal chemotherapy, suboptimal surgery and optimal chemotherapy, and surgery and chemotherapy were suboptimal.
    Results: In total, 19.9% (n=700) of ovarian cancer patients were diagnosed with FIGO stage I. Median age was 60 years (range 18-96), 47.1% had FIGO stage IA and 47.9% had stage IC, with 37.1% high grade serous histology. Optimal surgical quality increased over time from 19.9% to 54.1%. The optimal surgery population increased from 42.2% to 70.9%. Disease free survival improved significantly in the optimal surgery population (84% after 48 months vs 71% in the suboptimal surgery population). Overall survival increased with 91% after 48 months in the optimal surgery population versus 76% in the suboptimal surgery population. In total, 20.7% of patients were undertreated concerning systemic treatment and 1% overtreated. Optimal chemotherapy standard was administered increasingly over time (71.4-80.8%). Disease free survival and overall survival were prolonged with adjuvant chemotherapy. The optimal surgery/chemotherapy subgroup increased from 37.9% to 54.1% with significantly longer disease free survival and overall survival (overall survival at 48 months: optimal surgery and chemotherapy 93%; suboptimal surgery and chemotherapy 68%).
    Conclusion: Although QS-OVAR data showed that the quality of therapy has improved over the years, not all surgical standards were met in nearly 50% of patients. The steady increase in the optimal surgery and chemotherapy collective is an important tool for improvement of prognosis of ovarian cancer patients.
    MeSH term(s) Humans ; Female ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Neoplasm Staging ; Ovarian Neoplasms/pathology ; Prognosis ; Disease-Free Survival ; Progression-Free Survival ; Chemotherapy, Adjuvant
    Language English
    Publishing date 2023-07-03
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1070385-8
    ISSN 1525-1438 ; 1048-891X
    ISSN (online) 1525-1438
    ISSN 1048-891X
    DOI 10.1136/ijgc-2022-004233
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top